Eureka AIR delivers breakthrough ideas for toughest innovation challenges, trusted by R&D personnel around the world.

Compositions and methods for donor selection and prognosis of acute graft-versus-host disease

A donor, prognostic technology, applied in the fields of biochemical equipment and methods, microbial determination/examination, pharmaceutical formulations, etc.

Pending Publication Date: 2020-11-27
DUKE UNIV
View PDF0 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, additional biomarkers are needed to determine the risk associated with the development of GVHD

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Compositions and methods for donor selection and prognosis of acute graft-versus-host disease
  • Compositions and methods for donor selection and prognosis of acute graft-versus-host disease
  • Compositions and methods for donor selection and prognosis of acute graft-versus-host disease

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0109] Sample collection, RNA extraction, reverse transcription, real-time PCR and sequencing of PCR products

[0110] The study was performed using a cohort consisting of 192 human subjects undergoing allogeneic HCT and 114 corresponding donors from multiple centers. Plasma samples were collected from Duke University Medical Center, Dana-Farber Cancer Institute, and the Blood and Marrow Transplant Clinical Trials Network. The miRNA profiling set consisted of 19 HCT patients at Duke University Medical Center who had developed aGVHD and 23 HCT patients who had never developed aGVHD (non-GVHD). Another cohort of 15 non-GVHD and 15 aGVHD pre-onset aGVHD samples from Dana-Farber Cancer Institute was used to perform independent open array assays to validate candidate miRNAs identified from Duke samples. The miR-142-3p identification set included 6 aGVHD and 6 non-GVHD patients, and a corresponding donor for each recipient from the Dana-Farber Cancer Institute. The miR-142-3p vali...

Embodiment 2

[0119] Profiling of candidate miRNAs using a high-throughput platform

[0120] The microRNA sequence-specific anti-miRNA bead capture method was used to purify microRNA from plasma ( figure 1 A). RT-PCR inhibitors and degraded RNA fragments commonly found in blood-related samples are washed out from the final eluate. In addition, probe-based real-time PCR methods ( figure 1 B) and open array PCR chip ( figure 1 C) for improved specificity and throughput. The platform was validated by sequencing five random microRNA PCR products from plasma microRNAs from healthy donors. Sequencing results showed that the platform could efficiently and specifically detect microRNAs from plasma samples (92%<specificity≤100%). MicroRNA profiling was performed on the platform using plasma from 19 patients who had developed GVHD and 23 timepoint-matched non-GVHD subjects.

[0121] Most plasma microRNAs showed similar expression patterns between disease and non-disease ( figure 1 D). General...

Embodiment 3

[0124] Donor and recipient plasma miR-142-3p ratios are associated with aGVHD development

[0125] The expression level of miR-142-3p in plasma from aGVHD patients was determined to be lower ( figure 1 D, 1E). The ratio of plasma miR-142-3p between donors and recipients was on average 4-fold lower in the aGVHD group compared with those from the non-GVHD group. The expression level of miR-142-3p was also determined using plasma samples obtained on days 0 and 28 after BMT. In both cases, a low ratio of miR-142-3p levels in plasma before BMT was associated with aGVHD ( figure 2 A). Furthermore, the miR-142-3p ratio between day 0 and day 28 after BMT showed a similar pattern between the aGVHD group and the non-GVHD group ( figure 2 B). These data suggest that low miR-142-3p levels in donor plasma are a risk factor for the development of aGVHD after donor selection and BMT. Furthermore, plasma miR-142-3p levels of recipients after BMT can be used to monitor the development ...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

Provided are compositions and methods for donor selection and prognosis of acute graft-versus-host disease. Provided is a method, which comprises obtaining a first biological sample from a first subject at risk of GVHD; detecting a level of miR-142-3p in the sample; and determining a risk of, prognosis of, or diagnosis of GVHD in the first subject. Provided also is a method for selecting a stem cell transplant donor, which comprises obtaining a first biological sample from a first subject and a second biological sample from a second subject, detecting a level of miR-142-3p in the first biological sample and the second biological sample; determining a ratio of the level of miR-142-3p in the second biological sample to the level of miR-142-3p in the first biological sample; determining the likelihood of the first subject will develop GVHD based on the ratio; and selecting a transplant donor based on the ratio.

Description

[0001] cross-referenced application [0002] This application claims the benefit of U.S. Provisional Application No. 62 / 659,807, filed April 19, 2018, the entire contents of which are incorporated herein by reference. [0003] sequence listing [0004] This application contains a Sequence Listing that has been submitted in ASCII format via EFS-Web and is hereby incorporated by reference in its entirety. The ASCII copy, created on April 19, 2019, is named DU6176PCT_Seq_Listing_ST25.txt and is 2,186 bytes in size. [0005] Statement Regarding Federally Funded Research [0006] This invention was made with Government support under Federal Grant No. AI119707 awarded by NIH / NIAID. The Federal Government has certain rights in this invention. technical field [0007] Compositions and methods for donor selection, diagnosis, prognosis, and risk determination of acute graft-versus-host disease in a subject are provided. [0008] Background of the invention [0009] Allogeneic bone...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): C12Q1/6883
CPCC12Q1/6883C12Q2600/178C12Q2600/118A61K35/28
Inventor 何有文王宇N·赵
Owner DUKE UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com